- 2020-10-30 12:44:00Z
PHILADELPHIA, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. continues its investigation of potential securities claims on behalf of investors of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) to determine whether the Company engaged in securities fraud or other unlawful business practices. ZOSANO INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMPANY'S SECURITIES BETWEEN FEBRUARY 13, 2017 AND SEPTEMBER 30, 2020, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM'S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, BUSINESS DEVELOPMENT, (215) 792-6676, EXT....
AstraZeneca said it would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany's Cheplapharm Arzneimittel GmbH. AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drug portfolio in a bid to streamline its business. The agreement with Cheplapharm supports AstraZeneca's strategy of focusing on newer medicines in main therapy areas, the drugmaker said.
- 2020-10-29 18:22:48Z
Months before the Trump administration separated thousands of families at the U.S.-Mexico border, a "pilot program" in Texas left child-welfare officials scrambling to find empty beds for babies taken from their parents in a preview of bigger problems to come, according to a report released Thursday by congressional Democrats. Documents in the report suggest Health and Human Services officials weren't told by the Department of Homeland Security why shelters were receiving more children taken from their parents in late 2017. It has since been revealed that DHS was operating a pilot program in El Paso, Texas, that prosecuted parents for crossing the border illegally and took their...
- 2020-10-29 00:08:00Z
Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included CBER OTAT staff together with the APstem team, focused on the development plan for AP-Skin-01, a novel "off-the-shelf" allogeneic stem cell product derived from adult pluripotent stem cells (APSCs™) for the initial treatment of diabetic...
Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas, the report said. Pfizer's Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month. The U.S. drugmaker said this week if trials are successful the company expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.
Your email address will not be published. Required fields are marked with *